Drugs / DTaP-IPV/Hib Combined vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02274285 | Oct 2014 → May 2016 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV/Hib Combined vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02274285 ↗ |
| Modality | Vaccine | “DTaP-IPV/Hib pentavalent vaccine” PMID 32307307 ↗ Apr 2020 |
| Route | Subcutaneous | “Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously” NCT02274285 ↗ |